Advice
The marketing authorisation for rosiglitazone/metformin 2mg/500mg, 2mg/1g, 4mg/1g (Avandamet) has been withdrawn.
 

The SMC Advice has been removed from the website.

On 23 September, 2010, the European Medicines Agency’s (EMA) Committee on Medicinal Products for Human Use (CHMP) recommended the suspension of the marketing authorisation for Avandia, Avandamet and Avaglim (rosiglitazone) as the benefits no longer outweigh the risks.

www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf

"

Medicine details

Medicine name:
rosiglitazone/metformin 2mg/500mg, 2mg/1g, 4mg/1g (Avandamet)
SMC ID:
281/06
Indication:
Type 2 diabetes mellitus
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Endocrine system
Submission type
Abbreviated
Status
Withdrawn
Date advice published:
10 July 2006